Abstract: The present invention relates to oral liquid formulations of Enzalutamide or pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient. Further, the invention relates to providing an economical and technically advanced dosage form over existing dosage forms. In addition, the present invention also provides an improved process for preparation of Enzalutamide oral liquid formulation. The present invention further provides such compositions for the treatment of for the treatment of patients with metastatic castration-resistant prostate cancer who have previously received docetaxel.

Abstract: The present invention relates to an oral soft-gelatin capsule dosage form of Nintedanib and pharmaceutically acceptable salt thereof. The invention also relates to provide patient-compliant, economical and technically advanced dosage form over existing marketed dosage form as well as nearest prior-arts. Moreover, the dissolution rate and stability of the patient compliant Nintedanib formulation, prepared as per the present invention, is proven higher when compared to prior art inventions. Furthermore, the present invention also provides an oily dispersion without using lecithin is prepared by a process which is relatively simple, easy to commercially manufacture, and functionally reproducible.